Pub Date : 2026-01-28DOI: 10.1016/j.ctarc.2026.101118
Dongyong Zhu, Yusheng Guo, Weiwei Liu, Bingxin Gong, Yi Li, Shanshan Jiang, Yuanxi Li, Lianwei Miao, Lingli Li, Lian Yang
Background: The prognostic role of the triglyceride-glucose-body mass index (TyG-BMI), a surrogate marker for insulin resistance, in small cell lung cancer (SCLC) patients treated with immune checkpoint inhibitors remains undefined.
Methods: In this multicenter retrospective study, SCLC patients who initiated first-line chemoimmunotherapy or chemotherapy alone between March 2015 and December 2023 were enrolled. The association between baseline TyG-BMI index and survival was analyzed using Kaplan-Meier and Cox regression methods. A prognostic nomogram was developed and validated via time-dependent ROC and calibration analyses.
Results: Among 437 patients, a low TyG-BMI index was significantly associated with improved overall survival (OS) in the chemoimmunotherapy cohort (P < 0.001). In the chemotherapy-alone cohort, a high index predicted worse progression-free survival (PFS, P = 0.031). The TyG-BMI index was an independent prognostic factor for both PFS (HR = 1.44, P = 0.005) and OS (HR = 1.42, P = 0.002). The nomogram demonstrated good predictive accuracy for OS (9-18 month AUCs: 0.72-0.73; C-index=0.66, 95 % CI: 0.63-0.69) and was well-calibrated.
Conclusion: The baseline TyG-BMI index is a treatment-specific prognostic biomarker. A low index identifies SCLC patients most likely to achieve long-term survival benefit from chemoimmunotherapy, offering a practical tool for risk stratification and therapeutic guidance.
{"title":"Prognostic value of the baseline triglyceride-glucose-body mass index in small cell lung cancer undergoing chemoimmunotherapy: A multicenter retrospective study.","authors":"Dongyong Zhu, Yusheng Guo, Weiwei Liu, Bingxin Gong, Yi Li, Shanshan Jiang, Yuanxi Li, Lianwei Miao, Lingli Li, Lian Yang","doi":"10.1016/j.ctarc.2026.101118","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101118","url":null,"abstract":"<p><strong>Background: </strong>The prognostic role of the triglyceride-glucose-body mass index (TyG-BMI), a surrogate marker for insulin resistance, in small cell lung cancer (SCLC) patients treated with immune checkpoint inhibitors remains undefined.</p><p><strong>Methods: </strong>In this multicenter retrospective study, SCLC patients who initiated first-line chemoimmunotherapy or chemotherapy alone between March 2015 and December 2023 were enrolled. The association between baseline TyG-BMI index and survival was analyzed using Kaplan-Meier and Cox regression methods. A prognostic nomogram was developed and validated via time-dependent ROC and calibration analyses.</p><p><strong>Results: </strong>Among 437 patients, a low TyG-BMI index was significantly associated with improved overall survival (OS) in the chemoimmunotherapy cohort (P < 0.001). In the chemotherapy-alone cohort, a high index predicted worse progression-free survival (PFS, P = 0.031). The TyG-BMI index was an independent prognostic factor for both PFS (HR = 1.44, P = 0.005) and OS (HR = 1.42, P = 0.002). The nomogram demonstrated good predictive accuracy for OS (9-18 month AUCs: 0.72-0.73; C-index=0.66, 95 % CI: 0.63-0.69) and was well-calibrated.</p><p><strong>Conclusion: </strong>The baseline TyG-BMI index is a treatment-specific prognostic biomarker. A low index identifies SCLC patients most likely to achieve long-term survival benefit from chemoimmunotherapy, offering a practical tool for risk stratification and therapeutic guidance.</p>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"101118"},"PeriodicalIF":2.4,"publicationDate":"2026-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146123714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-18DOI: 10.1016/j.ctarc.2026.101104
Inès Cherradi, Mohamed Ichou, Mohammed Squalli Houssaini, Nabil Ismaili
{"title":"Corrigendum to Management of immune-related adverse events under PD-1/PD-L1 inhibitors: Insights from a Moroccan real-world experience: Cancer Treatment and Research Communications, Volume 44, (2025), Article number 100978.","authors":"Inès Cherradi, Mohamed Ichou, Mohammed Squalli Houssaini, Nabil Ismaili","doi":"10.1016/j.ctarc.2026.101104","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101104","url":null,"abstract":"","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"101104"},"PeriodicalIF":2.4,"publicationDate":"2026-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146003217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-14DOI: 10.1016/j.ctarc.2026.101097
Song Wang, Jiahua He, Yuanbin Liao, Weihao Li, Weili Zhang, Da Kang, Weifeng Wang, Ruowei Wang, Chi Zhou, Junzhong Lin, Leen Liao, Jianhong Peng, Yuguang Lin
{"title":"Corrigendum to: Impact of TGF-β1 on tumor immune microenvironment and prognosis in colorectal liver oligometastasis: Cancer Treatment and Research Communications 46 (2026) 101059.","authors":"Song Wang, Jiahua He, Yuanbin Liao, Weihao Li, Weili Zhang, Da Kang, Weifeng Wang, Ruowei Wang, Chi Zhou, Junzhong Lin, Leen Liao, Jianhong Peng, Yuguang Lin","doi":"10.1016/j.ctarc.2026.101097","DOIUrl":"https://doi.org/10.1016/j.ctarc.2026.101097","url":null,"abstract":"","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":" ","pages":"101097"},"PeriodicalIF":2.4,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.ctarc.2025.101085
Chen Chang , Guodong Fang , Jianyuan Lei , Lele Liu , Guorong Wang , Wensheng Li
Background
The BRAF V600E mutation is the most frequent driver alteration in papillary thyroid carcinoma (PTC) and plays an important role in diagnosis, risk stratification, and treatment planning. Commonly used detection methods include immunohistochemistry (IHC), amplification-refractory mutation system PCR (AMRS-PCR), and droplet digital PCR (ddPCR). However, their relative performance and their ability to identify low-frequency mutations have not been fully clarified.
Methods
This retrospective study included 1571 patients diagnosed with PTC between December 2021 and January 2025. All patients underwent IHC testing, and 871 also received AMRS-PCR for BRAF V600E detection. Sixty cases with discordant IHC and AMRS-PCR results were further analyzed using ddPCR. Detection rates, concordance, sensitivity, specificity, and variant allele frequency (VAF) were compared across the three methods.
Results
Among the 871 patients with both IHC and AMRS-PCR results, the overall concordance rate was 93.2 %, and 59 cases showed discordant findings. ddPCR confirmed the presence of BRAF V600E in 24 discordant cases (40.7 %). The ddPCR positivity rate was higher in the IHC-negative and AMRS-PCR-positive group than in the IHC-positive and AMRS-PCR-negative group (52.2 % vs. 33.3 %, P = 0.033), and the former group also showed a markedly higher VAF (mean 6.97 % vs. 2.82 %). AMRS-PCR demonstrated better sensitivity and specificity (75.0 % and 85.7 %) than IHC (25.0 % and 14.3 %).
Conclusion
AMRS-PCR provides greater sensitivity and specificity than IHC for detecting BRAF V600E mutations and is appropriate for routine molecular testing. ddPCR offers excellent sensitivity for low-frequency mutations and is valuable for resolving discordant results. A multimodal testing strategy may improve detection accuracy and support personalized management of patients with PTC.
{"title":"Comparative analysis of IHC, AMRS-PCR, and ddPCR for BRAF V600E mutation detection in papillary thyroid carcinoma","authors":"Chen Chang , Guodong Fang , Jianyuan Lei , Lele Liu , Guorong Wang , Wensheng Li","doi":"10.1016/j.ctarc.2025.101085","DOIUrl":"10.1016/j.ctarc.2025.101085","url":null,"abstract":"<div><h3>Background</h3><div>The BRAF V600E mutation is the most frequent driver alteration in papillary thyroid carcinoma (PTC) and plays an important role in diagnosis, risk stratification, and treatment planning. Commonly used detection methods include immunohistochemistry (IHC), amplification-refractory mutation system PCR (AMRS-PCR), and droplet digital PCR (ddPCR). However, their relative performance and their ability to identify low-frequency mutations have not been fully clarified.</div></div><div><h3>Methods</h3><div>This retrospective study included 1571 patients diagnosed with PTC between December 2021 and January 2025. All patients underwent IHC testing, and 871 also received AMRS-PCR for BRAF V600E detection. Sixty cases with discordant IHC and AMRS-PCR results were further analyzed using ddPCR. Detection rates, concordance, sensitivity, specificity, and variant allele frequency (VAF) were compared across the three methods.</div></div><div><h3>Results</h3><div>Among the 871 patients with both IHC and AMRS-PCR results, the overall concordance rate was 93.2 %, and 59 cases showed discordant findings. ddPCR confirmed the presence of BRAF V600E in 24 discordant cases (40.7 %). The ddPCR positivity rate was higher in the IHC-negative and AMRS-PCR-positive group than in the IHC-positive and AMRS-PCR-negative group (52.2 % vs. 33.3 %, <em>P</em> = 0.033), and the former group also showed a markedly higher VAF (mean 6.97 % vs. 2.82 %). AMRS-PCR demonstrated better sensitivity and specificity (75.0 % and 85.7 %) than IHC (25.0 % and 14.3 %).</div></div><div><h3>Conclusion</h3><div>AMRS-PCR provides greater sensitivity and specificity than IHC for detecting BRAF V600E mutations and is appropriate for routine molecular testing. ddPCR offers excellent sensitivity for low-frequency mutations and is valuable for resolving discordant results. A multimodal testing strategy may improve detection accuracy and support personalized management of patients with PTC.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101085"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Osimertinib is a standard treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC). The EGFR C797S mutation is one of the most common resistant mechanisms to osimertinib. Based on our preclinical data, the safety and efficacy of brigatinib combined with panitumumab was evaluated in phase 1/2 study.
Method
This open-label phase 1/2 study enrolled patients with osimertinib-resistant EGFR-mutated NSCLC, with phase 1 dose escalation part, followed by phase 2 dose expansion part. The primary endpoint was the incidence of dose-limiting toxicities for phase 1 part, and objective response rate for phase 2 part.
Result
A total of 5 patients were enrolled between Dec 2020 and Jun 2021. Patients had received a median of 4 (range, 1–7) prior lines of treatment, no patient received prior immune checkpoint inhibitors. Median washout period from last dose of osimertinib was 10 days (range, 2–393). Three (60%) patients experienced early onset pulmonary event (EOPE) (grade [Gr] 2, n = 1; Gr 3, n = 2), all of which occurred during brigatinib monotherapy period. All cases with EOPE improved with brigatinib interruption for Gr 2, and systemic corticosteroid treatment for Gr 3. The efficacy to study treatment were PD in all 5 patients, with median progression-free survival of 1.7 months (95% CI, 1.2 to 3.4). Exploratory ctDNA analysis showed the decrease in relative allele frequency (C797S/exon19 deletion) between pre- and post-treatment (n = 3).
Conclusion
The clinical development of this combination strategy was discontinued, as brigatinib treatment was not feasible in patients with advanced EGFR-mutated NSCLC resistant to osimertinib.
背景：奥西替尼是晚期egfr突变的非小细胞肺癌（NSCLC）的标准治疗方法。EGFR C797S突变是对奥西替尼最常见的耐药机制之一。基于我们的临床前数据，我们在1/2期研究中评估了布加替尼联合帕尼单抗的安全性和有效性。方法：这项开放标签的1/2期研究纳入了奥西替尼耐药egfr突变的NSCLC患者，包括1期剂量递增部分，随后是2期剂量扩大部分。主要终点是第一阶段的剂量限制性毒性发生率和第二阶段的客观缓解率。结果：在2020年12月至2021年6月期间，共有5名患者入组。患者先前接受的治疗中位数为4（范围，1-7），没有患者先前接受免疫检查点抑制剂。最后一次给药后的中位洗脱期为10天（范围2-393天）。3例（60%）患者发生早发性肺事件（EOPE） （grade [Gr] 2, n = 1; Gr 3, n = 2），均发生在布加替尼单药治疗期间。所有EOPE患者在2级布加替尼中断治疗和3级全身皮质类固醇治疗后均得到改善。5例患者的研究疗效均为PD，中位无进展生存期为1.7个月（95% CI, 1.2 ~ 3.4）。探索性ctDNA分析显示，治疗前后相对等位基因频率（C797S/exon19缺失）降低（n = 3）。结论：由于布加替尼治疗对奥西替尼耐药的晚期egfr突变NSCLC患者不可行，该联合策略的临床开发已停止。
{"title":"Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation","authors":"Hiroki Izumi , Tomohiro Sakamoto , Ken Uchibori , Kazumi Nishino , Jun Sakakibara-Konishi , Ryohei Katayama , Shogo Nomura , Shingo Matsumoto , Hibiki Udagawa , Yuji Shibata , Tetsuya Sakai , Kaname Nosaki , Yoshitaka Zenke , Kiyotaka Yoh , Seiji Niho , Koichi Goto","doi":"10.1016/j.ctarc.2026.101105","DOIUrl":"10.1016/j.ctarc.2026.101105","url":null,"abstract":"<div><h3>Background</h3><div>Osimertinib is a standard treatment for advanced <em>EGFR</em>-mutated non-small cell lung cancer (NSCLC). The <em>EGFR</em> C797S mutation is one of the most common resistant mechanisms to osimertinib. Based on our preclinical data, the safety and efficacy of brigatinib combined with panitumumab was evaluated in phase 1/2 study.</div></div><div><h3>Method</h3><div>This open-label phase 1/2 study enrolled patients with osimertinib-resistant <em>EGFR</em>-mutated NSCLC, with phase 1 dose escalation part, followed by phase 2 dose expansion part. The primary endpoint was the incidence of dose-limiting toxicities for phase 1 part, and objective response rate for phase 2 part.</div></div><div><h3>Result</h3><div>A total of 5 patients were enrolled between Dec 2020 and Jun 2021. Patients had received a median of 4 (range, 1–7) prior lines of treatment, no patient received prior immune checkpoint inhibitors. Median washout period from last dose of osimertinib was 10 days (range, 2–393). Three (60%) patients experienced early onset pulmonary event (EOPE) (grade [Gr] 2, <em>n</em> = 1; Gr 3, <em>n</em> = 2), all of which occurred during brigatinib monotherapy period. All cases with EOPE improved with brigatinib interruption for Gr 2, and systemic corticosteroid treatment for Gr 3. The efficacy to study treatment were PD in all 5 patients, with median progression-free survival of 1.7 months (95% CI, 1.2 to 3.4). Exploratory ctDNA analysis showed the decrease in relative allele frequency (C797S/exon19 deletion) between pre- and post-treatment (<em>n</em> = 3).</div></div><div><h3>Conclusion</h3><div>The clinical development of this combination strategy was discontinued, as brigatinib treatment was not feasible in patients with advanced <em>EGFR</em>-mutated NSCLC resistant to osimertinib.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101105"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146008864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.ctarc.2025.101091
Tânia Rodrigues , Joana Albuquerque , Joana Cardoso , Ivo Sousa-Ferreira , João Paulo Martins , José Luís Passos Coelho
Purpose
The prognostic value of SMAD4 in pancreatic cancer has been evaluated in several studies. However, the conclusions remain controversial. Therefore, we aimed to evaluate the prognostic value of the SMAD4 gene in pancreatic cancer to aid in the design of therapeutic strategies.
Methods
This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria and the proposed methodology was registered on PROSPERO. An electronic search was made in MEDLINE (via PubMed), Web of Science and Google Scholar to identify all relevant studies. Eligible studies were those written in English including patients with Pancreatic Ductal Adenocarcinoma (PDAC), who underwent pancreatic surgery with curative intent and provided data on SMAD4 gene status or SMAD4 protein expression and its association to prognosis, measured by overall survival (OS). The effect measure of interest was the hazard ratio (HR) for OS between PDAC with or without SMDA4 mutations.
Results
A total of 24 studies on SMAD4, with 4340 samples, were included in this systematic review and meta-analysis. Our pooled results demonstrated that patients with tumours with SMAD4 alteration had significantly worse prognosis for OS (HR= 1.43, 95% CI = 1.17–1.76, p-value = 0.002).
Conclusion
This systematic review and meta-analysis support the use of driver mutations in the SMAD4 gene as a prognostic marker for pancreatic cancer.
目的研究SMAD4在胰腺癌中的预后价值。然而，这些结论仍然存在争议。因此，我们旨在评估SMAD4基因在胰腺癌中的预后价值，以帮助设计治疗策略。方法本综述遵循系统评价和荟萃分析首选报告项目（PRISMA）标准，建议的方法在PROSPERO上注册。在MEDLINE（通过PubMed）、Web of Science和b谷歌Scholar进行电子检索，以确定所有相关研究。符合条件的研究是用英文撰写的，包括胰导管腺癌（PDAC）患者，他们接受了胰腺手术，并提供SMAD4基因状态或SMAD4蛋白表达及其与预后的关联数据，以总生存期（OS）衡量。感兴趣的效应测量是带有或不带有SMDA4突变的PDAC之间OS的风险比（HR）。结果本系统综述和荟萃分析共纳入24项关于SMAD4的研究，共纳入4340份样本。我们的汇总结果显示，SMAD4改变的肿瘤患者的OS预后明显较差（HR= 1.43, 95% CI = 1.17-1.76， p值= 0.002）。本系统综述和荟萃分析支持SMAD4基因驱动突变作为胰腺癌预后标志物的应用。
{"title":"Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis","authors":"Tânia Rodrigues , Joana Albuquerque , Joana Cardoso , Ivo Sousa-Ferreira , João Paulo Martins , José Luís Passos Coelho","doi":"10.1016/j.ctarc.2025.101091","DOIUrl":"10.1016/j.ctarc.2025.101091","url":null,"abstract":"<div><h3>Purpose</h3><div>The prognostic value of <em>SMAD4</em> in pancreatic cancer has been evaluated in several studies. However, the conclusions remain controversial. Therefore, we aimed to evaluate the prognostic value of the <em>SMAD4</em> gene in pancreatic cancer to aid in the design of therapeutic strategies.</div></div><div><h3>Methods</h3><div>This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria and the proposed methodology was registered on PROSPERO. An electronic search was made in MEDLINE (via PubMed), Web of Science and Google Scholar to identify all relevant studies. Eligible studies were those written in English including patients with Pancreatic Ductal Adenocarcinoma (PDAC), who underwent pancreatic surgery with curative intent and provided data on <em>SMAD4</em> gene status or SMAD4 protein expression and its association to prognosis, measured by overall survival (OS). The effect measure of interest was the hazard ratio (HR) for OS between PDAC with or without SMDA4 mutations.</div></div><div><h3>Results</h3><div>A total of 24 studies on <em>SMAD4</em>, with 4340 samples, were included in this systematic review and meta-analysis. Our pooled results demonstrated that patients with tumours with <em>SMAD4</em> alteration had significantly worse prognosis for OS (HR= 1.43, 95% CI = 1.17–1.76, p-value = 0.002).</div></div><div><h3>Conclusion</h3><div>This systematic review and meta-analysis support the use of driver mutations in the <em>SMAD4</em> gene as a prognostic marker for pancreatic cancer.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101091"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The CJLSG1901 phase 2 study evaluated efficacy and safety of pembrolizumab plus pemetrexed in older populations. A novel first-line approach for older patients with metastatic non-squamous non-small cell lung cancer (NSCLC) was assessed.
Methods
A subgroup analysis was conducted to determine the efficacy and safety of pembrolizumab plus pemetrexed in older patients with metastatic non-squamous NSCLC according to programmed cell death-ligand 1 (PD-L1) status (<1 % vs 1 %–49 %) using data from the CJLSG1901 study.
Results
Forty-nine patients were enrolled between July 2020 and May 2022. The objective responserate (ORR) was 36.7 %. The median progression-free survival (PFS) was and median overall survival (OS) were 7.6 months and 19.4 months,respectively. Twenty-one patients had a PD-L1 expression of <1 %, whereas 28 had a PD-L1 expression of 1 %–49 %. The median age, sex, Eastern Clinical Oncology Group performance status, and stage were similar in both groups. ORRs were 23.8 % in the PD-L1 <1 % group and 46.4 % in the PD-L1 1 %–49 % group. Median PFS were 4.4 months in the PD-L1 <1 % group and 7.8 months in the PD-L1 1 %–49 % group. Median OS were 19.4 months and 19.1 months in these groups, respectively. Adverse events (AEs) of any grade were observed in all patients, regardless of PD-L1 status. AE severerity was comparable between the groups. Severe treatment-related AEs occurred in five patients (25 %) in the PD-L1 <1 % group and seven patients (25 %) in the PD-L1 1 %–49 % group.
Conclusions
The ORR was higher in the PD-L1 1 %–49 % group; however, the PFS and OS were similar in both groups.
{"title":"Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study","authors":"Yoshihito Kogure , Hiroya Hashimoto , Satoshi Ikeda , Toshiyuki Harada , Aoi Hino , Satoru Miura , Yasuhiro Goto , Keiichi Fujiwara , Nobuyuki Katakami , Kaoru Kubota , Naohiko Murata , Masahide Mori , Takashi Abe , Akiko M. Saito , Nobuyuki Yamamoto , Hideo Saka , Masashi Kondo","doi":"10.1016/j.ctarc.2026.101094","DOIUrl":"10.1016/j.ctarc.2026.101094","url":null,"abstract":"<div><h3>Background</h3><div>The CJLSG1901 phase 2 study evaluated efficacy and safety of pembrolizumab plus pemetrexed in older populations. A novel first-line approach for older patients with metastatic non-squamous non-small cell lung cancer (NSCLC) was assessed.</div></div><div><h3>Methods</h3><div>A subgroup analysis was conducted to determine the efficacy and safety of pembrolizumab plus pemetrexed in older patients with metastatic non-squamous NSCLC according to programmed cell death-ligand 1 (PD-L1) status (<1 % vs 1 %–49 %) using data from the CJLSG1901 study.</div></div><div><h3>Results</h3><div>Forty-nine patients were enrolled between July 2020 and May 2022. The objective responserate (ORR) was 36.7 %. The median progression-free survival (PFS) was and median overall survival (OS) were 7.6 months and 19.4 months,respectively. Twenty-one patients had a PD-L1 expression of <1 %, whereas 28 had a PD-L1 expression of 1 %–49 %. The median age, sex, Eastern Clinical Oncology Group performance status, and stage were similar in both groups. ORRs were 23.8 % in the PD-L1 <1 % group and 46.4 % in the PD-L1 1 %–49 % group. Median PFS were 4.4 months in the PD-L1 <1 % group and 7.8 months in the PD-L1 1 %–49 % group. Median OS were 19.4 months and 19.1 months in these groups, respectively. Adverse events (AEs) of any grade were observed in all patients, regardless of PD-L1 status. AE severerity was comparable between the groups. Severe treatment-related AEs occurred in five patients (25 %) in the PD-L1 <1 % group and seven patients (25 %) in the PD-L1 1 %–49 % group.</div></div><div><h3>Conclusions</h3><div>The ORR was higher in the PD-L1 1 %–49 % group; however, the PFS and OS were similar in both groups.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101094"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146023104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Therapeutic resistance remains a serious challenge in breast cancer, and abnormal c-mesenchymal epithelial transition factor (c-Met) receptor tyrosine kinase (RTK) activation contributes to therapeutic resistance in many. Ubiquitin-specific peptidase 8 (USP8) has emerged as a modulator of RTK stability through deubiquitination and endosomal trafficking, and preclinical studies show that inhibition of USP8 speeds up ubiquitin-dependent degradation of RTKs, including c-Met and EGFR, suppresses PI3K/Akt and MAPK signaling, and reverses resistance phenotypes. In this review, we summarize mechanistic evidence for USP8 regulation of c-Met and related RTKs, explore preclinical studies that assess inhibition of USP8 as a strategy to sensitize RTK-driven tumors, and highlight translational limitations such as drug selectivity, toxicity, dosing, pharmacodynamics biomarkers, and patient selection that must be addressed prior to a clinical trial in breast cancer. While the therapeutic targeting of USP8 is promising, direct validation in breast cancer models and the development of robust pharmacodynamic markers and inhibitors that are clinically graded remain crucial next phase.
{"title":"Unraveling the potential of USP8 as a therapeutic target for overcoming c-Met-mediated resistance in breast cancer: A review","authors":"Doris Nnenna Amuji , Suleiman Zakari , Ayomikun Joshua Pirisola , Olubanke Olujoke Ogunlana , Emeka E.J. Iweala","doi":"10.1016/j.ctarc.2025.101089","DOIUrl":"10.1016/j.ctarc.2025.101089","url":null,"abstract":"<div><div>Therapeutic resistance remains a serious challenge in breast cancer, and abnormal c-mesenchymal epithelial transition factor (c-Met) receptor tyrosine kinase (RTK) activation contributes to therapeutic resistance in many. Ubiquitin-specific peptidase 8 (USP8) has emerged as a modulator of RTK stability through deubiquitination and endosomal trafficking, and preclinical studies show that inhibition of USP8 speeds up ubiquitin-dependent degradation of RTKs, including c-Met and EGFR, suppresses PI3K/Akt and MAPK signaling, and reverses resistance phenotypes. In this review, we summarize mechanistic evidence for USP8 regulation of c-Met and related RTKs, explore preclinical studies that assess inhibition of USP8 as a strategy to sensitize RTK-driven tumors, and highlight translational limitations such as drug selectivity, toxicity, dosing, pharmacodynamics biomarkers, and patient selection that must be addressed prior to a clinical trial in breast cancer. While the therapeutic targeting of USP8 is promising, direct validation in breast cancer models and the development of robust pharmacodynamic markers and inhibitors that are clinically graded remain crucial next phase.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101089"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145909973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1016/j.ctarc.2025.101084
Huang Zhizhuo , Jin Ling , Liu Wei , Sun Lirong , Zhang Baoxi , Zhuang Shuquan , Yuan Xiaojun , Jia Yueping , Zhang Yonghong
To analyze the clinical features of early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in pediatric patients and to summarize the efficacy evaluation of the 2017 protocol by the China Net Childhood Lymphoma (CNCL) Non-Hodgkin Lymphoma (NHL) 2017-LBL for ETP-LBL. Methods Clinical data of 19 children with ETP-LBL admitted to CNCL from May 2017 to August 2023 were retrospectively collected. Results The median age of onset was 10 years (4.5–13 years), including 16 males (84.2 %). All patients were in stage IV and were treated with high-risk chemotherapy regimen. 11 of them (57.9 %) underwent hematopoietic stem cell transplantation (HSCT). The proportion of leukemia stage in the HSCT group was significantly higher than that in the chemotherapy group (72.7 % vs. 25.0 %), and the central nervous system (CNS) status was CNS2/3 in the HSCT group (100 % vs. 50 %).The 3-year overall survival (OS) and event free survival (EFS) were (93.8 ± 0.61) % and (88.2 ± 0.78) %, respectively. Conclusion Over 50 % of pediatric ETP-LBL patients received HSCT, with their long-term survival rates comparable to the chemotherapy group.
分析儿科患者早期t细胞前体急性淋巴细胞白血病/淋巴瘤（ETP-ALL/LBL）的临床特征，总结中国儿童淋巴瘤网（CNCL）非霍奇金淋巴瘤（NHL） 2017-LBL 2017方案对ETP-LBL的疗效评价。方法回顾性收集2017年5月至2023年8月收治的19例ETP-LBL患儿的临床资料。结果中位发病年龄为10岁（4.5 ~ 13岁），其中男性16例（84.2%）。所有患者均为IV期，接受高危化疗方案。11例（57.9%）行造血干细胞移植（HSCT）。HSCT组白血病分期比例明显高于化疗组（72.7% vs. 25.0%），中枢神经系统（CNS）状态为CNS2/3 （100% vs. 50%）。3年总生存率（OS）和无事件生存率（EFS）分别为（93.8±0.61）%和（88.2±0.78）%。结论：超过50%的儿科ETP-LBL患者接受了HSCT，其长期生存率与化疗组相当。
{"title":"Efficacy evaluation of the 2017 protocol by the China Net Childhood Lymphoma in treating early T cell precursors-lymphoblastic lymphoma in pediatric patients","authors":"Huang Zhizhuo , Jin Ling , Liu Wei , Sun Lirong , Zhang Baoxi , Zhuang Shuquan , Yuan Xiaojun , Jia Yueping , Zhang Yonghong","doi":"10.1016/j.ctarc.2025.101084","DOIUrl":"10.1016/j.ctarc.2025.101084","url":null,"abstract":"<div><div>To analyze the clinical features of early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in pediatric patients and to summarize the efficacy evaluation of the 2017 protocol by the China Net Childhood Lymphoma (CNCL) Non-Hodgkin Lymphoma (NHL) 2017-LBL for ETP-LBL. Methods Clinical data of 19 children with ETP-LBL admitted to CNCL from May 2017 to August 2023 were retrospectively collected. Results The median age of onset was 10 years (4.5–13 years), including 16 males (84.2 %). All patients were in stage IV and were treated with high-risk chemotherapy regimen. 11 of them (57.9 %) underwent hematopoietic stem cell transplantation (HSCT). The proportion of leukemia stage in the HSCT group was significantly higher than that in the chemotherapy group (72.7 % vs. 25.0 %), and the central nervous system (CNS) status was CNS2/3 in the HSCT group (100 % vs. 50 %).The 3-year overall survival (OS) and event free survival (EFS) were (93.8 ± 0.61) % and (88.2 ± 0.78) %, respectively. Conclusion Over 50 % of pediatric ETP-LBL patients received HSCT, with their long-term survival rates comparable to the chemotherapy group.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"46 ","pages":"Article 101084"},"PeriodicalIF":2.4,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145910719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号